Related Experiment Videos
Breast cancer genes: therapeutic strategies
1Department of Cell Biology, Vanderbilt University, Nashville, Tennessee 37232, USA. jeff.holt@mcmail.vanderbilt.edu
Abstract:
Although effective treatments for breast cancer predated the identification of causative molecular defects in humans, it is widely hoped that an understanding and/or manipulation of the key genetic events will lead to even more effective therapies or even cures. Powerful methods of positional cloning and gene identification have identified the breast cancer genes, BRCA1 and BRCA2, which together are responsible for the majority of cases of hereditary breast and ovarian cancer. Although the BRCA1 gene is rarely mutated in sporadic breast or ovarian cancer, levels of BRCA1 mRNA and protein are markedly decreased in the majority of sporadic cases of cancer. This suggests that hereditary and sporadic breast cancer share common genetic themes and that treatments aimed at increasing levels of BRCA1 or BRCA2 may be useful for both hereditary and sporadic cancers. We have demonstrated that gene transfer of wild-type BRCA1 inhibits the growth of sporadic breast and ovarian cancer cells and suppresses growth of established breast and ovarian tumor models in nude mice. Mutant BRCA1 genes do not inhibit growth or suppress tumor, providing additional evidence that BRCA1 is a tumor-suppressor gene. Strategies designed to increase BRCA1 expression or development of BRCA1-mimetic agents may be ultimately useful as therapeutic approaches.
Insights
Restoring BRCA1 gene function can inhibit the growth of sporadic breast and ovarian cancer cells. This suggests that increasing BRCA1 levels may offer a therapeutic strategy for both hereditary and sporadic cancers.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Effective breast cancer treatments exist, but understanding genetic defects offers hope for improved therapies and cures.
- BRCA1 and BRCA2 genes are identified as key players in hereditary breast and ovarian cancers.
- Reduced BRCA1 mRNA and protein levels are observed in most sporadic breast and ovarian cancers, suggesting shared genetic pathways with hereditary forms.
Purpose of the Study:
- To investigate the therapeutic potential of restoring BRCA1 gene function in sporadic breast and ovarian cancers.
- To determine if BRCA1 acts as a tumor suppressor gene in sporadic cancer models.
- To explore strategies for increasing BRCA1 expression as a potential cancer treatment.
Main Methods:
- Gene transfer of wild-type BRCA1 into sporadic breast and ovarian cancer cells.
- Evaluation of tumor growth inhibition in established breast and ovarian tumor models in nude mice using both wild-type and mutant BRCA1.
- Assessment of BRCA1 mRNA and protein levels in sporadic cancer cases.
Main Results:
- Gene transfer of wild-type BRCA1 significantly inhibited the growth of sporadic breast and ovarian cancer cells.
- Wild-type BRCA1 gene transfer suppressed the growth of established breast and ovarian tumors in nude mice.
- Mutant BRCA1 genes failed to inhibit growth or suppress tumors, supporting its role as a tumor suppressor.
Conclusions:
- BRCA1 functions as a tumor suppressor gene.
- Increasing BRCA1 expression or utilizing BRCA1-mimetic agents may represent a viable therapeutic strategy for both hereditary and sporadic breast and ovarian cancers.
- Shared genetic mechanisms between hereditary and sporadic cancers warrant further investigation for targeted therapies.